# An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

> **NCT02574260** · PHASE2 · COMPLETED · sponsor: **BioVex Limited** · enrollment: 3 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Talimogene Laherparepvec

## Key facts

- **NCT ID:** NCT02574260
- **Lead sponsor:** BioVex Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2015-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574260, "An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02574260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*